Success Stories: Indian Senior Scientist in Pharmaceutical Sciences with Massive Citation Count of 1,444, Gets EB1-A and NIW Approvals with Our Team’s Efficient Case Preparation Strategy Quickly

Client’s Testimonial:

“Thank you very much for the update on the approval. This is very exciting news. Thank you for helping me to reach this stage.”

On November 29^th, 2021 and December 20^th, 2021, we received another EB-1A (Alien of Extraordinary Ability) and EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Pharmaceutical Sciences (Approval Notice).

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Senior Scientist

Country of Origin: India

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: November 29^th, 2021 (EB-1A) and December 20^th, 2021 (NIW)

Processing Time: 13 days (EB-1A) (Premium Processing Requested) and 6 months, 25 days (NIW)

Case Summary:

A senior scientist in pharmaceutical sciences from India wanted our help filing his NIW (National Interest Waiver) and EB1-A (Alien of Extraordinary Ability) petitions. Initially, he came to us with his NIW request which we helped him file in the month of May in 2021, and later we also helped him file an EB1-A in November of the same year. With premium processing upgrade and our diligent team effort, we were able to get him the approvals in less than the expected time for both the applications.

While the NIW category of the EB2 visa application requires the petitioner to prove their worth to the nation resulting in a labor certification and permanent job waiver, the EB1-A category requires the applicant to prove their extraordinary value for the proposed area of endeavor. Both of these categories thus requires careful case preparation and this is exactly where NAILG comes in. Our team was able to put together his petition for both the applications. Some of the things which were common to both of these were as follows:

A detailed explanation of his work in the area showing that he wanted to develop safe and effective drug delivery platforms including lipid-based nanoparticles, extracellular vesicles, oral biotherapeutics, and hydrogels through techniques such as microfluidics and high-performance liquid chromatography in order to facilitate improved targeting and dosage in pharmaceuticals for treating conditions such as rheumatoid arthritis, diabetes, and cancer.
Details of his major funding from the National Cancer Institute (NCI) of the National Institutes of Health.
Details of his publication history showing that his research has resulted in 8 peer-reviewed journal articles (3 first-authored and 2 co-first-authored), 1 first-authored book chapter, and 4 international patent applications.
Evidence showing that these publications have been cited a massive total of 1,444 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pharmaceutical sciences.
Evidence of 15 peer reviews conducted for prestigious scientific journals in his area of expertise.
Finally, 2 letters of recommendation each showing the worth of his research for the national and the world.

We were thus very happy to hear of his NIW approval in just 6 months and 25 days, and his EB1-A approval in just 13 days (Premium Processing Service). Our team wishes him the very best in every future endeavor.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.